Merit Medical Systems, Inc’s recently made public that its CFO AND TREASURER Parra Raul Jr. unloaded Company’s shares for reported $1.42 million on Jun 13 ’25. In the deal valued at $93.75 per share,15,181 shares were sold. As a result of this transaction, Parra Raul Jr. now holds 24,201 shares worth roughly $2.05 million.
Then, RAUL PARRA bought 15,181 shares, generating $1,423,219 in total proceeds.
Before that, Lampropoulos Fred P. sold 400 shares. Merit Medical Systems, Inc shares valued at $38,244 were divested by the President and CEO at a price of $95.61 per share. As a result of the transaction, Lampropoulos Fred P. now holds 1,045,628 shares, worth roughly $88.65 million.
JP Morgan initiated its Merit Medical Systems, Inc [MMSI] rating to an Overweight in a research note published on March 28, 2025; the price target was $120. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in mid December from “an Equal weight” to “an Overweight”. Robert W. Baird began covering MMSI with “an Outperform” recommendation on June 28, 2024. CL King started covering the stock on April 11, 2024. It rated MMSI as “a Buy”.
Price Performance Review of MMSI
On Friday, Merit Medical Systems, Inc [NASDAQ:MMSI] saw its stock fall -0.09% to $84.78. Over the last five days, the stock has gained 0.11%. Merit Medical Systems, Inc shares have fallen nearly -0.26% since the year began. Nevertheless, the stocks have fallen -12.34% over the past one year.
How much short interest is there in Merit Medical Systems, Inc?
A steep rise in short interest was recorded in Merit Medical Systems, Inc stocks on 2025-07-15, growing by 0.4 million shares to a total of 3.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.27 million shares. There was a rise of 10.81%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 07, 2024 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $87 price target.
